Grant: CIHR Fellowship
McGill University
$135,000.00
Exploring new mechanisms of lysosomal dysfunction and alpha-synuclein aggregation in Parkinson's Disease
EF 2016-17
Résumé
Parkinson's Disease (PD) is the second most frequent neurodegenerative disease, affecting 2% of population by age 65. PD is a progressive disease, which mainly manifests as motor dysfunction, but also leads to dementia in 20% of cases. This disorder strongly affects the capacity of patients to perform everyday tasks, such as writing or pouring a glass of water, making emotionally difficult to manage for patients and their families, and financially costly for the society. Current therapies only partially and temporarily correct motor difficulties, but they become inefficient as the disease progresses. New ways to treat the disease are needed, which can target the disease at the root to not only provide palliative but also curative treatment.
One molecular basis for most PD cases is the abnormal accumulation in the brain of an otherwise harmless protein present in our cells, called synuclein. Normally, cells will get rid of excess synuclein through their waste-management facility, the lysosome. But in PD patients, the lysosome is dysfunctional for unclear reasons, causing synuclein to accumulate. Some mutations in the DNA of PD patients alter the correct function of lysosomes, but why these mutations cause PD is unknown. The present project aims at understanding how these DNA mutations cause waste-management defects, synuclein accumulation, and ultimately PD. This project is new and ambitious, because despite their clear implication in PD, the DNA mutations we want to study have been mainly disregarded by PD research community.
Ultimately, our project will uncover new mechanisms that explain waste-management defects in PD. This will allow the design of novel and promising ways to increase waste-disposal capacities in the cells of PD patients, get rid of excess toxic synuclein, and prevent or even revert disease progression.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
362054
Name
Vanderperre Benoît
Region
Québec
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Exploring new mechanisms of lysosomal dysfunction and alpha-synuclein aggregation in Parkinson's Disease
Programtype2
Fellowship Programs
Orgnameinp2
McGill University
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Alpha-Synuclein; Autophagy; Biochemistry Of Lysosomes; Cell Culture; Crispr/Cas9 Gene Editing; Lysosome; Neurodegeneration; Parkinson'S Disease; Protein Aggregation
Abstract
Parkinson's Disease (PD) is the second most frequent neurodegenerative disease, affecting 2% of population by age 65. PD is a progressive disease, which mainly manifests as motor dysfunction, but also leads to dementia in 20% of cases. This disorder strongly affects the capacity of patients to perform everyday tasks, such as writing or pouring a glass of water, making emotionally difficult to manage for patients and their families, and financially costly for the society. Current therapies only partially and temporarily correct motor difficulties, but they become inefficient as the disease progresses. New ways to treat the disease are needed, which can target the disease at the root to not only provide palliative but also curative treatment.
One molecular basis for most PD cases is the abnormal accumulation in the brain of an otherwise harmless protein present in our cells, called synuclein. Normally, cells will get rid of excess synuclein through their waste-management facility, the lysosome. But in PD patients, the lysosome is dysfunctional for unclear reasons, causing synuclein to accumulate. Some mutations in the DNA of PD patients alter the correct function of lysosomes, but why these mutations cause PD is unknown. The present project aims at understanding how these DNA mutations cause waste-management defects, synuclein accumulation, and ultimately PD. This project is new and ambitious, because despite their clear implication in PD, the DNA mutations we want to study have been mainly disregarded by PD research community.
Ultimately, our project will uncover new mechanisms that explain waste-management defects in PD. This will allow the design of novel and promising ways to increase waste-disposal capacities in the cells of PD patients, get rid of excess toxic synuclein, and prevent or even revert disease progression.
Competitiondate
201611
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Vanderperre, Benoît
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~